- Home
- JANX vs ECX Comparison
JANX vs ECX Comparison
Compare JANX & ECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | ECX |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.8M | 742.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | JANX | ECX |
|---|---|---|
| Price | $13.29 | $1.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $57.36 | $3.20 |
| AVG Volume (30 Days) | 1.7M | ★ 4.1M |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,000,000.00 | ★ $822,663,229.00 |
| Revenue This Year | N/A | $782.65 |
| Revenue Next Year | N/A | $32.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.99 |
| 52 Week Low | $12.12 | $0.76 |
| 52 Week High | $44.83 | $3.25 |
Technical Indicators
Market Signals| Indicator | JANX | ECX |
|---|---|---|
| Relative Strength Index (RSI) | 36.48 | 40.69 |
| Support Level | $12.12 | $1.62 |
| Resistance Level | $14.16 | $1.92 |
| Average True Range (ATR) | 0.75 | 0.14 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 17.66 | 12.07 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.